SCHEMBL1787503

SCHEMBL1787503

CCOc1cc(Cl)c(C(N)=O)cc1-n1cccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 4/20 0.46
HCAR2 Q8TDS4 2/20 0.44
GHSR Q92847 1/20 0.44
HTT P42858 2/20 0.40
LMNA P02545 2/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
CAPN1 P07384 1/20 0.38
HCRTR1 O43613 2/20 0.38
HCRTR2 O43614 2/20 0.38
KCNH2 Q12809 1/20 0.37
SCN5A Q14524 1/20 0.37
GPR52 Q9Y2T5 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
G6PD P11413 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1786846 0.87 HCAR1 (0.47) HCAR1HCAR2GHSRLMNAHCRTR1
SCHEMBL1785351 0.86 CAPN1 (0.42) GHSRLMNAMKNK1MKNK2CAPN1
SCHEMBL1788949 0.83 IRAK4 (0.45) LMNAMKNK1MKNK2CAPN1KCNH2
SCHEMBL1786708 0.81 CAPN1 (0.47) GHSRHTTLMNAMKNK1MKNK2
SCHEMBL1789180 0.80 CAPN1 (0.42) HCAR1LMNAMKNK1MKNK2CAPN1
SCHEMBL1783427 0.77 CAPN1 (0.42) HCAR1LMNAMKNK1MKNK2CAPN1
SCHEMBL3706149 0.75 GHSR (0.41) GHSRHTTLMNAHCRTR1HCRTR2
SCHEMBL1784466 0.74 GHSR (0.42) HCAR1GHSRHTTLMNAHCRTR1
SCHEMBL2796786 0.73 NOTUM (0.45) LMNAKDM4EMEN1ALDH1A1GAA
SCHEMBL3702097 0.72 PTGDR (0.39) HCAR1LMNAKCNH2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R HCAR1 212/4885HCAR2 301/4885GHSR 2/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R HCAR1 1153/4885HCAR2 1883/4885GHSR 30/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R HCAR1 961/4885HCAR2 632/4885GHSR 59/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R HCAR1 212/4885HCAR2 301/4885GHSR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.